Posted by Michael Wonder on 18 Mar 2017
Institute for Clinical and Economic Review to produce "New Evidence Update" Including updated value-based price benchmarks for PCSK9 inhibitors to treat high cholesterol
17 March 2017 - Update will incorporate new data on outcomes for patients with atherosclerotic cardiovascular disease released during the March 17th American College of Cardiology conference.
With important new clinical evidence now available, the ICER has begun a "New Evidence Update" to its 2015 review of the comparative clinical effectiveness and value of PCSK9 inhibitors alirocumab (Praluent, Sanofi/Regeneron) and evolocumab (Repatha, Amgen).
The ICER update will assess newly-released data on the clinical efficacy of evolocumab in patients with atherosclerotic cardiovascular disease, but these trial results do not include data with which to update previous assessments of evidence for patients with familial hypercholesterolemia or those who are intolerant to statins. The New Evidence Update will include a re-calculation of the ICER value-based price benchmark for evolocumab. ICER will also be reaching out to the clinical and patient community to gain additional insights on the importance of the new data from these perspectives. The New Evidence Update will be released within eight weeks.
